top of page
SERVICES
CUSTOM TMA
ROUTINE PATHOLOGY
IHC / IMMUNOFLUORESCENCE
ISH / FISH
CONTRACTED SERVICES
PRIMARY IHC ANTIBODIES
PATHOLOGY FIELD
Hermatopathology
DETECTION SYSTEMS
ANCILLARIES
CONTROL TMA
MTU481
Multi tumor tissue array, 48 cases of 15 cancer types. Most types have duplicates or triplicates from different patients with grading and TNM staging data.
Price per slide:
$160
Species:
Human
Cases:
48
Cores:
48
Core Size:
1.5mm
Core Thickness:
4um
Rows:
6
Columns:
8
Format:
Intended Usage:
For research use only. Designed for IHC or ISH based protein or RNA tissue profiling in top 15 cancer types.
6
X
8
For illustration purpose only. Actual product may vary.
Notes:
All the tissues were fixed in 10% neutral buffered formalin for 24 hours and processed using identical SOPs. Sections were picked onto Superfrost Plus or APES coated Superfrost slides. They can be stored for use at 4C for up to six months from the date of shipment. There may be 5 to 10% of tissue core loss.
Bake at 60C for ~60 minutes before use. If antigen retrieving is needed, it is important to avoid direct-boiling and high pH or high strength antigen retrieving buffer. For availability of complimentary IHC data, please contact us at info@pantomics.com.
ARRAY POSITION | IMAGE | SEX | AGE | ANATOMIC SITE | PATHOLOGY | NATURE | GRADE | STAGE (TNM) |
|---|---|---|---|---|---|---|---|---|
A01 |  | M | 60 | Bladder, urinary | Transitional cell carcinoma | Malignant | II | T4N0M0 |
A02 |  | F | 30 | Breast | Invasive ductal carcinoma, tubular type | Malignant | I~II | T3N0M0 |
A03 |  | M | 45 | Lung | Small cell carcinoma | Malignant | T2N1M0 | |
A04 |  | M | 68 | Esophagus | Squamous cell carcinoma | Malignant | II | T2N0M0 |
A05 |  | F | 55 | Intestine, colon | Adenocarcinoma | Malignant | II | T3N1M0 |
A06 |  | M | 61 | Liver | Hepatocellular carcinoma | Malignant | I~II | T2N0M0 |
A07 |  | F | 58 | Ovary | Endometrioid adenocarcinoma | Malignant | III | T2N0M0 |
A08 |  | M | 75 | Prostate | Hyperplasia | Hyperplasia | ||
B01 |  | M | 61 | Bladder, urinary | Transitional cell carcinoma | Malignant | II | T3N0M0 |
B02 |  | F | 54 | Breast | Invasive lobular carcinoma | Malignant | I | T3N1M0 |
B03 |  | M | 58 | Lung | Squamous cell carcinoma | Malignant | II~III | T2N0M0 |
B04 |  | M | 66 | Esophagus | Squamous cell carcinoma | Malignant | I~II | T3N0M0 |
B05 |  | M | 67 | Intestine, colon | Adenocarcinoma | Malignant | II | T3N1M0 |
B06 |  | M | 29 | Liver | Hepatocellular carcinoma | Malignant | II | T4N0M0 |
B07 |  | F | 58 | Ovary | Serous cystadenocarcinoma | Malignant | I~II | T2N0M0 |
B08 |  | M | 69 | Prostate | Adenocarcinoma | Malignant | III | T2N0M0 |
C01 |  | M | 57 | Bladder, urinary | Transitional cell carcinoma | Malignant | I~II | T2N0M0 |
C02 |  | F | 43 | Breast | Invasive ductal carcinoma | Malignant | II | T3N1M0 |
C03 |  | M | 59 | Lung | Squamous cell carcinoma | Malignant | II | T2N1M0 |
C04 |  | M | 47 | Stomach | Adenocarcinoma | Malignant | II | T3N2M0 |
C05 |  | M | 76 | Intestine, colon | Adenocarcinoma | Malignant | III | T3N1M0 |
C06 |  | M | 55 | Liver | Hepatocellular carcinoma | Malignant | III | T3N0M0 |
C07 |  | F | 51 | Ovary | Adenocarcinoma | Malignant | II | T2N0M0 |
C08 |  | F | 55 | Skin | Normal | Normal | ||
D01 |  | F | 57 | Uterus, cervix | Squamous cell carcinoma | Malignant | III | T1N1M0 |
D02 |  | F | 39 | Breast | Invasive ductal carcinoma | Malignant | I | T4N1M0 |
D03 |  | F | 46 | Lung | Adenocarcinoma | Malignant | II~III | T3N1M0 |
D04 |  | M | 72 | Stomach | Adenocarcinoma | Malignant | II~III | T3N2M0 |
D05 |  | M | 73 | Intestine, rectum | Adenocarcinoma | Malignant | II | T2N0M0 |
D06 |  | M | 48 | Kidney | Clear cell carcinoma | Malignant | T1N0M0 | |
D07 |  | F | 43 | Uterus, endometrium | Adenocarcinoma | Malignant | II | T1N0M0 |
D08 |  | M | 58 | Skin | Squamous cell carcinoma | Malignant | I~II | T1N0M0 |
E01 |  | F | 31 | Uterus, cervix | Squamous cell carcinoma | Malignant | II~III | T2N0M0 |
E02 |  | F | 38 | Breast | Invasive ductal carcinoma | Malignant | III | T2N1M0 |
E03 |  | F | 50 | Lung | Adenocarcinoma | Malignant | III | T2N1M0 |
E04 |  | F | 54 | Stomach | Adenocarcinoma | Malignant | II | T3N2M0 |
E05 |  | M | 79 | Intestine, rectum | Adenocarcinoma | Malignant | II | T2N0M0 |
E06 |  | F | 64 | Kidney | Clear cell carcinoma | Malignant | T1N0M0 | |
E07 |  | F | 49 | Uterus, endometrium | Adenocarcinoma | Malignant | I~II | T2N0M0 |
E08 |  | M | 48 | Lymph node, inguinal | Metastatic melanoma | Malignant | ||
F01 |  | F | 52 | Uterus, cervix | Squamous cell carcinoma | Malignant | III | T1N0M0 |
F02 |  | F | 75 | Breast | Invasive ductal carcinoma | Malignant | III | T3N0M0 |
F03 |  | M | 80 | Lung | Adenocarcinoma | Malignant | II~III | T3N0M0 |
F04 |  | M | 20 | Intestine, small intestine | Adenocarcinoma | Malignant | I | T3N2M0 |
F05 |  | F | 65 | Intestine, rectum | Adenocarcinoma | Malignant | II | T2N0M0 |
F06 |  | M | 54 | Kidney | Clear cell carcinoma | Malignant | T2N0M0 | |
F07 |  | F | 58 | Uterus, endometrium | Adenocarcinoma | Malignant | III | T1N0M0 |
F08 |  | M | 28 | Tonsil | Tonsillitis | Inflammatory |
bottom of page